CDKN2A and lung neuroendocrine neoplasm: p16Ink4A overexpression was significantly associated with a shorter survival time in lung neuroendocrine tumors (HR = 0.08, 95% CI, 0.03 to 0.2, p <0.0001) (Fig 4A).